Gossamer Bio Inc
Suletud
SektorTervishoid
10.61 7,478.57
Ülevaade
Aktsiahinna muutus
24h
Min
10.46
Max
10.74
Sissetulek | 64M 17M |
|---|---|
Müük | -7.7M 9.2M |
Aktsiakasum | -0.2 |
Kasumimarginaal | 182.94 |
Töötajad | 161 |
EBITDA | -28M -71M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | -90.03% downside |
Turukapital | -391K 86M |
|---|---|
Eelmine avamishind | -7467.96 |
Eelmine sulgemishind | 10.61 |
Uudiste sentiment
By Acuity
79%
21%
314 / 339 Pingereas Healthcare
Gossamer Bio Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Gossamer Bio Inc Prognoos
Hinnasiht
By TipRanks
-90.03% langus
12 kuu keskmine prognoos
Keskmine 1.07 USD -90.03%
Kõrge 2 USD
Madal 0.28 USD
Põhineb 5 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
314 / 339 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
$
Ettevõttest Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.